These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4019576)

  • 21. Critical oxygen delivery levels during shock following normoxic and hyperoxic haemodilution with fluorocarbons or dextran.
    Faithfull NS; Cain SM
    Adv Exp Med Biol; 1987; 215():79-87. PubMed ID: 2445179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
    Police AM; Waxman K; Tominaga G
    Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inadequate subendocardial oxygen delivery during perfluorocarbon perfusion in a canine model of ischemia.
    Christensen CW; Reeves WC; Lassar TA; Schmidt DH
    Am Heart J; 1988 Jan; 115(1 Pt 1):30-7. PubMed ID: 3336983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red cell substitutes: hemoglobin solution or fluorocarbon?
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Rice CL; Moss GS
    J Trauma; 1982 Sep; 22(9):736-40. PubMed ID: 7120525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?
    Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluosol-DA, a perfluorochemical oxygen-transport fluid for the management of a trochanteric pressure sore in a Jehovah's Witness.
    Brown AS; Reichman JH; Spence RK
    Ann Plast Surg; 1984 May; 12(5):449-53. PubMed ID: 6742725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perfluorocarbon infusion in bleeding patients refusing blood transfusions.
    Waxman K; Tremper KK; Cullen BF; Mason GR
    Arch Surg; 1984 Jun; 119(6):721-4. PubMed ID: 6610401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.
    Swann KW; Ropper AH; Zervas NT
    Prog Clin Biol Res; 1983; 122():399-404. PubMed ID: 6348787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fluorocarbons with and without oxygen supplementation on cardiac hemodynamics and energetics.
    Rude RE; Bush LR; Tilton GD
    Am J Cardiol; 1984 Oct; 54(7):880-3. PubMed ID: 6207721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Fluosol-DA (20%) on skin flap survival in rats.
    Ramasastry SS; Waterman P; Angel MF; Futrell JW
    Ann Plast Surg; 1985 Nov; 15(5):436-42. PubMed ID: 4083744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O2 and CO2 solubility of the fluorocarbon emulsion fluosol-DA 20% and O2 and CO2 dissociation curves of blood-fluosol-DA 20% mixtures.
    Grote J; Steuer K; Müller R; Söntgerath C; Zimmer K
    Adv Exp Med Biol; 1985; 191():453-61. PubMed ID: 3938602
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemodilution and myocardial oxygen supply. The influence of fluosol-DA.
    Vogel H; Günther H; Harrison DK; Anderer W; Kessler M; Peter K
    Adv Exp Med Biol; 1989; 248():653-61. PubMed ID: 2782181
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative studies with Fluosol, Dextran, their mixture, or autologous blood in experimental hypovolemic shock.
    Madjidi A; Beisbarth H; Frey R
    Prog Clin Biol Res; 1983; 122():391-7. PubMed ID: 6192451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
    Tremper KK
    Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
    [No Abstract]   [Full Text] [Related]  

  • 35. U.S. clinical studies of the treatment of anemia with fluosol-DA 20%.
    Tremper KK; Cullen BF
    Artif Organs; 1984 Feb; 8(1):19-24. PubMed ID: 6367719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.
    Marelli TR
    Crit Care Nurse; 1994 Feb; 14(1):31-8. PubMed ID: 8194324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Fluosol-DA and hetastarch on local cerebral blood flow, cortical O2 availability and computerized EEG data during cerebral ischaemia.
    Tranmer BI; Iacobacci R; Feiler S
    Neurol Res; 1990 Mar; 12(1):17-22. PubMed ID: 1692110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perfluorochemical artificial blood as a volume expander in hypoxemic respiratory failure in dogs.
    Light RB; Perez-Padilla R; Kryger MH
    Chest; 1987 Mar; 91(3):444-9. PubMed ID: 3816321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Success in the radical resection of esophageal cancer with artificial blood infusion: case report.
    Mitsuno T; Kawa Y; Kita A; Kohno N
    Int Surg; 1981; 66(4):355-8. PubMed ID: 7345051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of artificial blood substitute (fluosol-DA 20%) in patients of cerebral ischemia].
    Oda Y; Murata T; Uchida Y; Mori K; Nagasawa S; Naruo Y; Asato R; Handa H
    No Shinkei Geka; 1982 Jun; 10(6):637-44. PubMed ID: 7121730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.